Baylor University Medical Center at Dallas, part of Baylor Scott & White Health, is currently enrolling patients in ENDCOV-I: The Study of the Use of Nintedanib in Slowing Lung Disease in Patients with Fibrotic or Non-Fibrotic Interstitial Lung Disease (ILD) Related to COVID-19. Baylor Dallas is one of seven trial sites throughout the United States.
The Centers for Disease Control and Prevention (CDC) has reported that an estimated 140 million Americans have been infected with the SARS-CoV-2 virus based on data collected from blood tests taken through January 2022. Many of these Americans are still feeling the after-effects of the virus known as post-acute sequelae of SARS-CoV-2 (PASC), or “long COVID.” The cases of PASC are becoming so common that lawmakers introduced a bill to fund research into the long-term effects of the disease and expand treatment resources for people experiencing them.
Gastroesophageal reflux disease (GERD) is estimated to affect nearly 20% of Americans. Recent advances in our understanding of GERD have changed clinical practice. Therefore, in February 2022, the American College of Gastroenterology (ACG) released an updated set of guidelines for the diagnosis and management of GERD. Research from Baylor University Medical Center (Baylor Dallas), part of Baylor Scott & White Health, helped shape these new practice guidelines.
